Drug Trial Radar · NCT03813056
Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy
Last checked: Nov 19, 2026Latest source record: Mar 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Planned (sponsor's estimate)
Start
Mar 25, 2019
Primary completion
Feb 1, 2025
Study completion Feb 1, 2025
Sponsor
- Lead sponsor
- Michael D. Straiko, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lions VisionGift Research; Eye Bank Association of America
- First posted
- Jan 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recently, published literature has reported that performing a descemetorhexis in combination with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas in patients with Fuchs Endothelial Corneal Dystrophy. Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor, has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil acts as an IOP-lowering drug by affecting aqueous outflow through the trabecular meshwork and Schlemm's canal. The goal of this study is to test the potential benefits of Ripasudil therapy administered after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. We believe that performing a standard DMEK surgery in combination with Ripasudil treatment in patients with Fuchs Endothelial Corneal Dystrophy could accelerate endothelial cell healing and clear edematous corneas faster, with less post-operative complications.
Conditions
- Fuchs Endothelial Dystrophy
Interventions
GlanatecDrug
Rho kinase Inhibitor
Optive, Ophthalmic SolutionDrug
artificial tears (placebo)
Descemet Membrane Endothelial KeratoplastyProcedure
Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to corneal clearanceTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Devers Eye Institute
Portland, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.